Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Staphylococcus aureus accessory gene regulator autoinducing peptide (AIP) is a macrocyclic thiolactone peptide that serves as the primary signaling molecule for the agr quorum-sensing system (Novick & Geisinger, 2008). Produced from the precursor protein AgrD and processed by the membrane protease AgrB, AIP is secreted into the extracellular environment to monitor bacterial population density (Thoendel et al., 2011). Upon reaching a critical threshold, AIP binds to the extracellular loops of its cognate transmembrane sensor kinase, AgrC, initiating a signal transduction cascade that activates the response regulator AgrA (Wang & Muir, 2016). This activation leads to a massive shift in the staphylococcal transcriptome, upregulating the production of secreted toxins, such as alpha-hemolysin and phenol-soluble modulins, while downregulating surface-associated colonization factors (Otto, 2014). Because the agr system is essential for the pathogenesis of acute S. aureus infections, AIP and its receptor AgrC are major targets for anti-virulence drug development. Therapeutic strategies include the use of synthetic AIP analogs or small molecules like Solonamide B to competitively inhibit AIP-AgrC binding, thereby “quenching” the quorum-sensing response and reducing tissue damage without exerting direct bactericidal pressure (Nielsen et al., 2014).
Competitive inhibition of the AgrC sensor kinase receptor to prevent the activation of the accessory gene regulator (agr) quorum-sensing system.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Staphylococcus aureus accessory gene regulator autoinducing peptide (AIP).